No, a new trial will cut this in half to $2.50, but it will be right back up there. Either way, this is a good drug that will be added to the menu of treating RCC.
Insiders are confident and they purchased a fair amount of share well over $6.
The ADCOM will be interesting as there is a lot of negativity out there and this sometimes can influence these members; it shouldn't, but they fall into hype just as easy as everyone else.
Hopefully they can see through the smog and AVEO has an answer for the difficult questions they will receive regarding how they came up with their Survival and OS numbers vs Sorafenib.
The safety profile looks good and I definitely think it is effective enough, just hope the FDA doesn't stiff them.
I am going with what I know and am trusting what I know to be the TRUTH.
These small biotechs sometimes are not transparent in any way and what they don't have to say, they won't; especially if it could have a negative impact.